The Life Sciences Report Examines 3D Signatures' Disruptive Technology for Prostate Cancer and Hodgkin's Lymphoma
SAN FRANCISCO, CA--(Marketwired - March 09, 2017) - 3D Signatures Inc. (TSX VENTURE: DXD) (OTCQB: TDSGF) continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. Included in this article is: 3D …